UNSPSC 51402305: Metanopirone or tandospirone

This classification denotes a serotonin agonist with the molecular structure C21H29N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 190230I669 chemically known as (1r*,2s*,3r*,4s*)-n-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-2,3-norbornanedicarboximide but generally known as tandospirone, which bears US NIH Compound Identifier 60558. European Medicines Agency schedules Tandospirone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10829MIG.

The term TANDOSPIRONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, no. 3, 1989, list 29. ). Metanopirone or tandospirone bears US NLM identifiers UMLS ID C0074676 and NCI Concept Code C87208. SMILES: C1CC2CC1C3C2C(=O)N(C3=O)CCCCN4CCN(CC4)C5=NC=CC=N5.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.

UNSPSC 51402305 Metanopirone or tandospirone is a Commodity code that covers pharmaceutical products, though recent state and local procurement activity under this code designation shows limited concrete alignment with the specific active pharmaceutical ingredients named. Instead, state and local buyers are soliciting broadly across pharmaceutical supply categories—naloxone and drug deactivation systems for community health, generic multi-source pharmaceuticals and OTC products through cooperative purchasing channels, and exploratory direct-to-manufacturer prescription programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across participating jurisdictions). The work involves procurement of finished pharmaceutical products and medical supplies for distribution through established wholesaler networks or direct delivery to public health facilities, with compliance requirements including cGMP certification, Drug Supply Chain Security Act adherence, FDA approval, and E-Verify employment verification.

Recent activity spans Florida, Texas, and the Upper Midwest. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2026. The Texas Health and Human Services Commission issued Request for Information HHS0017013 on April 3, 2026, to explore vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling early-stage market research before formal procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026, response deadline and July 1, 2026, contract effectiveness, requiring vendors to work through three authorized wholesalers and meet pricing competitiveness weighted at 75 percent of evaluation.